BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35069192)

  • 1. From AVATAR Mice to Patients: RC48-ADC Exerted Promising Efficacy in Advanced Gastric Cancer With HER2 Expression.
    Chen Z; Yuan J; Xu Y; Zhang C; Li Z; Gong J; Li Y; Shen L; Gao J
    Front Pharmacol; 2021; 12():757994. PubMed ID: 35069192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors.
    Xu Y; Wang Y; Gong J; Zhang X; Peng Z; Sheng X; Mao C; Fan Q; Bai Y; Ba Y; Jiang D; Yang F; Qi C; Li J; Wang X; Zhou J; Lu M; Cao Y; Yuan J; Liu D; Wang Z; Fang J; Shen L
    Gastric Cancer; 2021 Jul; 24(4):913-925. PubMed ID: 33945049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A HER2-targeted Antibody-Drug Conjugate, RC48-ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer.
    Hong X; Chen X; Wang H; Xu Q; Xiao K; Zhang Y; Chi Z; Liu Y; Liu G; Li H; Fang J; Lin T; Zhang Y
    Adv Sci (Weinh); 2023 Nov; 10(32):e2302377. PubMed ID: 37824205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer.
    Li W; Zhang K; Wang W; Liu Y; Huang J; Zheng M; Li L; Zhang X; Xu M; Chen G; Wang L; Zhang S
    J Exp Clin Cancer Res; 2024 Feb; 43(1):56. PubMed ID: 38403634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial.
    Wang Y; Gong J; Wang A; Wei J; Peng Z; Wang X; Zhou J; Qi C; Liu D; Li J; Lu M; Lu Z; Cao Y; Yuan J; Zhang R; Fang J; Zhang X; Shen L
    EClinicalMedicine; 2024 Feb; 68():102415. PubMed ID: 38235421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study.
    Wang P; Xia L
    BMC Cancer; 2023 Nov; 23(1):1083. PubMed ID: 37946161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer.
    Liu H; Zhou D; Liu D; Xu X; Zhang K; Hu R; Xiong P; Wang C; Zeng X; Wang L; Zhang S
    Cell Death Dis; 2024 Mar; 15(3):187. PubMed ID: 38443386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.
    Peng Z; Liu T; Wei J; Wang A; He Y; Yang L; Zhang X; Fan N; Luo S; Li Z; Gu K; Lu J; Xu J; Fan Q; Xu R; Zhang L; Li E; Sun Y; Yu G; Bai C; Liu Y; Zeng J; Ying J; Liang X; Xu N; Gao C; Shu Y; Ma D; Dai G; Li S; Deng T; Cui Y; Fang J; Ba Y; Shen L
    Cancer Commun (Lond); 2021 Nov; 41(11):1173-1182. PubMed ID: 34665942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery.
    Li L; Xu MZ; Wang L; Jiang J; Dong LH; Chen F; Dong K; Song HF
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12929-12937. PubMed ID: 33378043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway.
    Wu X; Xu L; Li X; Zhou Y; Han X; Zhang W; Wang W; Guo W; Liu W; Xu Q; Gu Y
    Cell Death Dis; 2023 Aug; 14(8):550. PubMed ID: 37620320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study.
    Nie C; Xu W; Guo Y; Gao X; Lv H; Chen B; Wang J; Liu Y; Zhao J; Wang S; He Y; Chen X
    BMC Cancer; 2023 Dec; 23(1):1239. PubMed ID: 38102538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03).
    Wen F; Lin T; Zhang P; Shen Y
    Front Oncol; 2023; 13():1233196. PubMed ID: 38269021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of disitamab vedotin after trastuzumab for HER2 positive breast cancer: a real-world data of retrospective study.
    Li C; Sun L; Liu Z; Sun H; Wang X; Yu Q; Yu Z
    Am J Cancer Res; 2024; 14(2):869-879. PubMed ID: 38455400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disitamab Vedotin (RC48) combined with bevacizumab for treatment of HR-negative/HER2-positive metastatic breast cancer with liver and brain involvement: A case report.
    Qu F; Liu Q; Lu R; Li W
    Front Oncol; 2023; 13():1245701. PubMed ID: 37711199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2-mediated MAPK pathway activation in gastric cancer cells and avatar mice.
    Chen Z; Liu Z; Zhang M; Huang W; Li Z; Wang S; Zhang C; Dong B; Gao J; Shen L
    Int J Cancer; 2019 Nov; 145(9):2440-2449. PubMed ID: 30957241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review.
    Li Y; Zhang J; Cai Z; Gao X; Zhang L; Lu Z; Wang X; Yu P; Li J; Fang F
    Front Oncol; 2023; 13():1286392. PubMed ID: 38074635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report.
    Wu Q; He L; Luo J; Jin W; Xu Y; Wang C
    Oncol Lett; 2022 Oct; 24(4):339. PubMed ID: 36039062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
    BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation.
    Hu Y; Chen F; Sun S; Xv L; Wang X; Wang M; Zhao S; Zhao Z; Li M
    Front Oncol; 2024; 14():1312634. PubMed ID: 38344201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disitamab vedotin, a novel HER2-directed antibody-drug conjugate in gastric cancer and other solid tumors.
    Hu Y; Zhu Y; Wei X; Tang C; Zhang W
    Drugs Today (Barc); 2022 Oct; 58(10):491-507. PubMed ID: 36305543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.